Table 1.
Participants demographics, clinical and biological characteristics
| Characteristic | FA (n = 39) |
|---|---|
| Demographics | |
| Age in years (Mean ± SE) | 26.8 ± 1.6 |
| Sex, Female (%) | 19 (48.7%) |
| Ethnicity, Caucasian (%) | 39 (100%) |
| Race, Hispanic (%) | 1 (2.5%) |
| Height in cm (Mean ± SE) | 166.9 ± 1.7 |
| Weight in kg (Mean ± SE) | 64.5 ± 2.6 |
| BMI in kg/m2 (Mean ± SE) | 22.9 ± 0.7 |
| Right- handed, % | 32 (82%) |
| Non-ambulatory, % | 8 (20.5%) |
| Clinical characteristics | |
| Disease duration in years (Mean ± SE) | 13.6 ± 1.1 |
| mFARS score (Mean ± SE) | 40.0 ± 2.0 |
| FA-ADL score (Mean ± SE) | 13.2 ± 0.9 |
| Dominant Hand 9 HPT score (Mean ± SE) | 71.8 ± 10.5 |
| Non-Dominant Hand 9 HPT score (Mean ± SE) | 58.8 ± 6.6 |
| 25FWT in seconds * (Mean ± SE) | 17.6 ± 3.7 |
| Biological characteristics | |
| GAA repeats (Mean ± SE) | 581.4 ± 40.1 |
| FXN (% of control individuals) * (Mean ± SE) | 40.0 ± 2.0 |
FXN and 25FWT data marked with an asterisk (*) were available for 28 participants.
mFARS modified Friedreich’s Ataxia Rating Scale, FA-ADL Friedreich Ataxia Rating Scale Activity of Daily Living, 9 HPT 9-Hole Peg Test, GAA Guanine-adenine-adenine, FXN frataxin, SE Standard Error.